

Rebecca C Arend

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8190372/publications.pdf>

Version: 2024-02-01

59
papers

2,397
citations

249298

26
h-index

242451

47
g-index

61
all docs

61
docs citations

61
times ranked

4102
citing authors

#	ARTICLE	IF	CITATIONS
1	International gynecologic cancer society (IGCS) 2021 meeting report. <i>Gynecologic Oncology</i> , 2022, 164, 208-211.	0.6	0
2	Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. <i>Advances in Therapy</i> , 2022, 39, 328-345.	1.3	9
3	Sequential modulation of the Wnt/ β -catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance. <i>Gynecologic Oncology</i> , 2022, 164, 170-180.	0.6	10
4	Homologous Recombination Deficiency: Concepts, Definitions, and Assays. <i>Oncologist</i> , 2022, 27, 167-174.	1.9	69
5	High-intermediate risk endometrial cancer: moving toward a molecularly based risk assessment profile. <i>International Journal of Clinical Oncology</i> , 2022, 27, 323-331.	1.0	3
6	Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOE. <i>Clinical Cancer Research</i> , 2022, 28, 1433-1445.	3.2	8
7	Circulating Tregs Accumulate in Omental Tumors and Acquire Adipose-Resident Features. <i>Cancer Immunology Research</i> , 2022, 10, 641-655.	1.6	4
8	TGF β 2 signaling networks in ovarian cancer progression and plasticity. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 139-161.	1.7	31
9	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. <i>Gynecologic Oncology</i> , 2021, 160, 817-826.	0.6	51
10	Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. <i>Gynecologic Oncology</i> , 2021, 160, 827-834.	0.6	20
11	Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. <i>Cancers</i> , 2021, 13, 1694.	1.7	1
12	Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 496-501.	0.6	7
13	Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1542-1549.	1.9	10
14	Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study. <i>Gynecologic Oncology</i> , 2021, 163, 85-92.	0.6	8
15	Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease. <i>Cancer Biology and Therapy</i> , 2021, 22, 89-105.	1.5	15
16	Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 709-717.	1.3	14
17	Neutralization of TGF β 2 Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 602-611.	1.9	5
18	Identifying a molecular profile to predict the risk of recurrence in high-intermediate risk endometrial cancer. <i>Cancer Medicine</i> , 2021, 10, 8238-8250.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology. <i>Journal of Tissue Engineering</i> , 2021, 12, 204173142110550.	2.3	3
20	A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: A Randomized, Controlled Trial. <i>Nutrition and Cancer</i> , 2020, 72, 584-594.	0.9	41
21	EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 301-307.	0.6	37
22	Harnessing Wnt signaling as a targetable therapy in epithelial ovarian cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 837-837.	0.7	2
23	The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 639-644.	1.9	41
24	Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 684-694.	1.2	6
25	Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 765-774.	0.6	43
26	Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 766.	1.7	18
27	Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. <i>Gynecologic Oncology</i> , 2020, 157, 578-584.	0.6	19
28	Inhibition of the Wnt/ β -catenin pathway enhances antitumor immunity in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091379.	1.4	21
29	Overcoming immune suppression with epigenetic modification in ovarian cancer. <i>Translational Research</i> , 2019, 204, 31-38.	2.2	9
30	Checkpoint inhibitors in ovarian cancer: A review of preclinical data. <i>Gynecologic Oncology Reports</i> , 2019, 29, 48-54.	0.3	47
31	Advancing Drug Development in Gynecologic Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 4874-4880.	3.2	18
32	A Review of the Role of Wnt in Cancer Immunomodulation. <i>Cancers</i> , 2019, 11, 771.	1.7	50
33	Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer. <i>Cancers</i> , 2019, 11, 668.	1.7	45
34	Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 2081-2094.	2.0	28
35	The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 175-188.	2.0	25
36	Neutrophilia and mortality in women with uterine carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1258-1263.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 591-602.	1.9	71
38	Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. <i>Molecular Cancer Research</i> , 2018, 16, 813-824.	1.5	42
39	The antitumor effects of entinostat in ovarian cancer require adaptive immunity. <i>Cancer</i> , 2018, 124, 4657-4666.	2.0	22
40	Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial. <i>Nutrients</i> , 2018, 10, 1187.	1.7	79
41	Endometrial cancer: Molecular markers and management of advanced stage disease. <i>Gynecologic Oncology</i> , 2018, 150, 569-580.	0.6	133
42	A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer. <i>Journal of Nutrition</i> , 2018, 148, 1253-1260.	1.3	96
43	Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey. <i>Gynecologic Oncology</i> , 2018, 150, 494-500.	0.6	5
44	FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer. <i>Cancer Letters</i> , 2018, 436, 75-86.	3.2	17
45	B7-H3-targeted ²¹² Pb radioimmunotherapy of ovarian cancer in preclinical models. <i>Nuclear Medicine and Biology</i> , 2017, 47, 23-30.	0.3	52
46	Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review. <i>Gynecologic Oncology Reports</i> , 2017, 20, 81-86.	0.3	44
47	Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. <i>Oncotarget</i> , 2017, 8, 44159-44170.	0.8	41
48	Implementation and utilization of the molecular tumor board to guide precision medicine. <i>Oncotarget</i> , 2017, 8, 57845-57854.	0.8	67
49	Nicosamide and its analogs are potent inhibitors of Wnt/ β -catenin, mTOR and STAT3 signaling in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 86803-86815.	0.8	64
50	Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2016, 143, 674-683.	0.6	24
51	The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. <i>Cancer Research</i> , 2016, 76, 3978-3988.	0.4	134
52	Ovarian cancer and the immune system – The role of targeted therapies. <i>Gynecologic Oncology</i> , 2016, 142, 349-356.	0.6	54
53	Targeting the Wnt/ β -catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. <i>Laboratory Investigation</i> , 2016, 96, 249-259.	1.7	58
54	Nicosamide Analogs for Treatment of Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1377-1385.	1.2	21

#	ARTICLE	IF	CITATIONS
55	PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2015, 139, 59-62.	0.6	45
56	Inhibition of Wnt/ β -catenin pathway by niclosamide: A therapeutic target for ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 112-120.	0.6	142
57	Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. <i>Gynecologic Oncology</i> , 2014, 133, 234-237.	0.6	17
58	Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?. <i>World Journal of Stem Cells</i> , 2014, 6, 441.	1.3	52
59	The Wnt/ β -catenin pathway in ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2013, 131, 772-779.	0.6	394